Aurinia Pharmaceuticals Inc
AUPH15.150USD
-0.180-1.17%
收盘 01/09, 16:00（美东）报价延迟15分钟
2.00B总市值
26.33市盈率 TTM
关于 Aurinia Pharmaceuticals Inc 公司
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Aurinia Pharmaceuticals Inc简介
公司代码AUPH
公司名称Aurinia Pharmaceuticals Inc
上市日期Jul 16, 2001
CEOGreenleaf (Peter S)
员工数量130
证券类型Ordinary Share
年结日Jul 16
公司地址#140, 14315 - 118 Avenue
城市EDMONTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编T5L 4S6
电话12507442487
网址https://www.auriniapharma.com
公司代码AUPH
上市日期Jul 16, 2001
CEOGreenleaf (Peter S)
Aurinia Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
720.08K
+52215.00%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
184.38K
+8173.00%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-2825.00%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-142976.00%
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Max) Donley
Mr. Matthew (Max) Donley
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey A. Bailey
Mr. Jeffrey A. Bailey
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
720.08K
+52215.00%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
184.38K
+8173.00%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-2825.00%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-142976.00%
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Max) Donley
Mr. Matthew (Max) Donley
Chief Operating Officer
Chief Operating Officer
--
--
收入明细
单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 1月7日 周三
更新时间: 1月7日 周三
持股股东
股东类型
持股股东
持股股东
占比
Tang Capital Management, LLC
8.59%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.72%
New Enterprise Associates (NEA)
3.01%
Arrowstreet Capital, Limited Partnership
2.56%
其他
76.16%
持股股东
持股股东
占比
Tang Capital Management, LLC
8.59%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.72%
New Enterprise Associates (NEA)
3.01%
Arrowstreet Capital, Limited Partnership
2.56%
其他
76.16%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
15.27%
Hedge Fund
15.04%
Investment Advisor
12.88%
Corporation
4.96%
Research Firm
3.21%
Venture Capital
3.03%
Individual Investor
2.48%
Pension Fund
0.78%
Bank and Trust
0.31%
其他
42.05%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
445
66.60M
50.51%
+1.59M
2025Q3
456
66.87M
50.55%
+7.38M
2025Q2
441
59.25M
53.54%
-3.86M
2025Q1
434
64.06M
48.83%
-3.20M
2024Q4
431
60.29M
49.51%
-113.45K
2024Q3
429
60.37M
47.88%
+2.19M
2024Q2
432
58.67M
47.42%
+718.51K
2024Q1
426
57.94M
45.47%
-7.82M
2023Q4
439
56.12M
43.33%
+3.78M
2023Q3
448
52.25M
45.32%
-2.45M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Tang Capital Management, LLC
11.33M
8.59%
+1.30M
+12.96%
Sep 30, 2025
ILJIN SNT Co., Ltd.
6.54M
4.96%
-984.75K
-13.10%
Aug 12, 2025
BlackRock Institutional Trust Company, N.A.
6.22M
4.72%
-241.10K
-3.73%
Sep 30, 2025
New Enterprise Associates (NEA)
3.97M
3.01%
--
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
3.37M
2.56%
+2.30M
+213.54%
Sep 30, 2025
State Street Investment Management (US)
2.69M
2.04%
-101.33K
-3.63%
Sep 30, 2025
Two Sigma Investments, LP
1.83M
1.39%
+1.48M
+417.21%
Sep 30, 2025
The Vanguard Group, Inc.
1.53M
1.16%
-163.37K
-9.65%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.49M
1.13%
-91.36K
-5.79%
Sep 30, 2025
Marshall Wace LLP
1.48M
1.12%
+1.38M
+1272.51%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Virtus LifeSci Biotech Products ETF
2.56%
Janus Henderson Small Cap Growth Alpha ETF
2.33%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.09%
ALPS Medical Breakthroughs ETF
0.7%
ProShares Ultra Nasdaq Biotechnology
0.26%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.26%
SPDR S&P International Small Cap ETF
0.2%
Vanguard US Multifactor ETF
0.18%
Invesco Nasdaq Biotechnology ETF
0.17%
Avantis US Small Cap Equity ETF
0.16%
查看更多
Virtus LifeSci Biotech Products ETF
占比2.56%
Janus Henderson Small Cap Growth Alpha ETF
占比2.33%
Janus Henderson Small/Mid Cap Growth Alpha ETF
占比1.09%
ALPS Medical Breakthroughs ETF
占比0.7%
ProShares Ultra Nasdaq Biotechnology
占比0.26%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
占比0.26%
SPDR S&P International Small Cap ETF
占比0.2%
Vanguard US Multifactor ETF
占比0.18%
Invesco Nasdaq Biotechnology ETF
占比0.17%
Avantis US Small Cap Equity ETF
占比0.16%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Aurinia Pharmaceuticals Inc的前五大股东是谁？
Aurinia Pharmaceuticals Inc 的前五大股东如下：
Tang Capital Management, LLC持有股份：11.33M，占总股份比例：8.59%。
ILJIN SNT Co., Ltd.持有股份：6.54M，占总股份比例：4.96%。
BlackRock Institutional Trust Company, N.A.持有股份：6.22M，占总股份比例：4.72%。
New Enterprise Associates (NEA)持有股份：3.97M，占总股份比例：3.01%。
Arrowstreet Capital, Limited Partnership持有股份：3.37M，占总股份比例：2.56%。
Tang Capital Management, LLC持有股份：11.33M，占总股份比例：8.59%。
ILJIN SNT Co., Ltd.持有股份：6.54M，占总股份比例：4.96%。
BlackRock Institutional Trust Company, N.A.持有股份：6.22M，占总股份比例：4.72%。
New Enterprise Associates (NEA)持有股份：3.97M，占总股份比例：3.01%。
Arrowstreet Capital, Limited Partnership持有股份：3.37M，占总股份比例：2.56%。
Aurinia Pharmaceuticals Inc的前三大股东类型是什么？
Aurinia Pharmaceuticals Inc 的前三大股东类型分别是：
Tang Capital Management, LLC
ILJIN SNT Co., Ltd.
BlackRock Institutional Trust Company, N.A.
Tang Capital Management, LLC
ILJIN SNT Co., Ltd.
BlackRock Institutional Trust Company, N.A.
有多少机构持有Aurinia Pharmaceuticals Inc(AUPH)的股份？
截至2025Q4，共有445家机构持有Aurinia Pharmaceuticals Inc的股份，合计持有的股份价值约为66.60M，占公司总股份的50.51%。与2025Q3相比，机构持股有所增加，增幅为-0.04%。
哪个业务部门对Aurinia Pharmaceuticals Inc的收入贡献最大？
在FY2024，--业务部门对Aurinia Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
